Eli Lilly’s relentless pipeline-building drive has continued with a licensing deal for Hanmi’s sonefpeglutide, in phase 2 for short bowel syndrome.
Revolution Medicines’ pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.
ASCO today brings good news for patients with localised prostate cancer, as early use of J&J’s ARPI offers a 19 month increase in median survival.
ASCO today brings good news for patients with localised prostate cancer, as early use of J&J’s ARPI offers a 19 month increase in median survival.
Akeso and Summit’s PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.
Millions of women with a breast cancer diagnosis could safely avoid chemotherapy that would not be effective, thanks to a genomics test.
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844